<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="cfr.xsl"?>
<CFRGRANULE xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:noNamespaceSchemaLocation="CFRMergedXML.xsd">
  <FDSYS>
    <CFRTITLE>21</CFRTITLE>
    <CFRTITLETEXT>Food and Drugs</CFRTITLETEXT>
    <VOL>9</VOL>
    <DATE>2013-04-01</DATE>
    <ORIGINALDATE>2013-04-01</ORIGINALDATE>
    <COVERONLY>false</COVERONLY>
    <TITLE>Additional requirements for biometrics.</TITLE>
    <GRANULENUM>1311.116</GRANULENUM>
    <HEADING>Section 1311.116</HEADING>
    <ANCESTORS>
      <PARENT HEADING="Title 21" SEQ="3">Food and Drugs</PARENT>
      <PARENT HEADING="CHAPTER II" SEQ="2">DRUG ENFORCEMENT ADMINISTRATION, DEPARTMENT OF JUSTICE</PARENT>
      <PARENT HEADING="PART 1311" SEQ="1">REQUIREMENTS FOR ELECTRONIC ORDERS AND PRESCRIPTIONS</PARENT>
      <PARENT HEADING="Subpart C" SEQ="0">Electronic Prescriptions</PARENT>
    </ANCESTORS>
  </FDSYS>
  <SECTION>
    <PRTPAGE P="169"/>
    <SECTNO>§ 1311.116</SECTNO>
    <SUBJECT>Additional requirements for biometrics.</SUBJECT>
    <P>(a) If one of the factors used to authenticate to the electronic prescription application is a biometric as described in § 1311.115, it must comply with the following requirements.</P>
    <P>(b) The biometric subsystem must operate at a false match rate of 0.001 or lower.</P>
    <P>(c) The biometric subsystem must use matching software that has demonstrated performance at the operating point corresponding with the false match rate described in paragraph (b) of this section, or a lower false match rate. Testing to demonstrate performance must be conducted by the National Institute of Standards and Technology or another DEA-approved government or nongovernment laboratory. Such testing must comply with the requirements of paragraph (h) of this section.</P>
    <P>(d) The biometric subsystem must conform to Personal Identity Verification authentication biometric acquisition specifications, pursuant to NIST SP 800-76-1 as incorporated by reference in § 1311.08, if they exist for the biometric modality of choice.</P>
    <P>(e) The biometric subsystem must either be co-located with a computer or PDA that the practitioner uses to issue electronic prescriptions for controlled substances, where the computer or PDA is located in a known, controlled location, or be built directly into the practitioner's computer or PDA that he uses to issue electronic prescriptions for controlled substances.</P>

    <P>(f) The biometric subsystem must store device ID data at enrollment (<E T="03">i.e.</E>, biometric registration) with the biometric data and verify the device ID at the time of authentication to the electronic prescription application.</P>
    <P>(g) The biometric subsystem must protect the biometric data (raw data or templates), match results, and/or non-match results when authentication is not local. If sent over an open network, biometric data (raw data or templates), match results, and/or non-match results must be:</P>
    <P>(1) Cryptographically source authenticated;</P>
    <P>(2) Combined with a random challenge, a nonce, or a time stamp to prevent replay;</P>
    <P>(3) Cryptographically protected for integrity and confidentiality; and</P>
    <P>(4) Sent only to authorized systems.</P>
    <P>(h) Testing of the biometric subsystem must have the following characteristics:</P>
    <P>(1) The test is conducted by a laboratory that does not have an interest in the outcome (positive or negative) of performance of a submission or biometric.</P>
    <P>(2) Test data are sequestered.</P>
    <P>(3) Algorithms are provided to the testing laboratory (as opposed to scores or other information).</P>
    <P>(4) The operating point(s) corresponding with the false match rate described in paragraph (b) of this section, or a lower false match rate, is tested so that there is at least 95% confidence that the false match and non-match rates are equal to or less than the observed value.</P>
    <P>(5) Results of the testing are made publicly available.</P>
  </SECTION>
</CFRGRANULE>
